Element Solutions Inc closed Tuesday up nearly 10% to $42.56 — the stock's best single session in months — after Q1 earnings topped both estimates and revenue expectations. The result capped a week that saw ESI gain almost 12% and extend its one-month rally to 28%. Yet even as bulls celebrated the print, the options market sent an unusually sharp defensive signal, creating one of the week's more interesting push-pull setups in specialty chemicals.
The most striking read from this week is in options. Put/call buying has swung to its most defensive posture in months, with the PCR jumping to 2.86 — more than three standard deviations above its 20-day average of 1.02. That is a sharp move. As recently as late March, the PCR was sitting below 0.5, reflecting bullish skew. The flip coincides almost exactly with the earnings catalyst: either options traders are chasing downside protection into an already-elevated price, or there is residual hedging from pre-earnings positioning that hasn't unwound. Either way, the read from the derivatives market is far more defensive than the stock's 12% week implies.
Short interest tells a notably less aggressive story. Short interest fell roughly 9% over the week to around 4.8% of the free float — back from the 5.5–5.7% range that held through most of early-to-mid April. That drawdown began as the stock rallied hard, with short positions down from a peak of ~5.7% of float on April 17 to current levels. The borrow market reflects none of the squeeze characteristics sometimes associated with sharp short covering: cost to borrow is a negligible 0.43%, and availability in the lending pool is more than ample. The ORTEX short score has also edged lower all week to 43.8, its lowest reading in the 10-day window, consistent with short-side pressure easing rather than building. Shorts are not piling in on the rally — they are retreating.
The Street appears broadly supportive, and the post-earnings reaction is prompting fresh target upgrades. Truist Securities raised its target to $47 this morning while reiterating Buy — the most recent and significant move, lifting the target well above the current price from a prior $38. The mean analyst target now runs at $44, a modest premium to the current $42.56. Bulls point to the Electronics segment, which grew sales 11% year-over-year on AI and data centre demand, and to the Industrial & Specialty division where margins expanded 420 basis points to 23.7%. Bears counter that EV-related weakness in power electronics and currency drag — with 77% of sales generated outside the US — remain structural headwinds. The factor score picture is mixed: the dividend score ranks in the 82nd percentile, the short score rank sits in the 19th percentile (meaning shorts are relatively light versus the broader universe), while the EV/EBIT and EPS surprise ranks are softer at 24 and 39 respectively.
The institutional registry offers a useful longer lens. BlackRock and Vanguard combined hold over 21% of shares, with both adding modestly to positions in the March quarter. T. Rowe Price added a more meaningful 1.39 million shares, and Invesco built 2.15 million shares — the largest reported addition among the top 15. The CEO and CFO both sold stock in late February at prices in the $34–$37 range, well below this week's close; those sales look mechanical given their scale and timing relative to the earnings calendar rather than a directional signal on valuation.
The earnings print itself validated the bull case on the top line, with the company issuing 2026 adjusted EBITDA guidance of $665–$685 million and lifting capex to $75–$100 million. The next scheduled event is May 4. What to watch from here is whether the PCR normalises as post-earnings hedges roll off, or whether the put skew proves prescient as the stock tests analyst targets less than 4% above the current price.
See the live data behind this article on ORTEX.
Open ESI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
